The more recent reports demonstrated that treatment with second-generation inhibitors of the 20S proteasome (delanzomib, carfilzomib and ixazomib) showed strong anti-tumor effects in KIT-dependent GIST cell lines as well as patient-derived tumor xenograft (PDX), including in imatinib-resistant models (Rausch et al., 2020). The gene discussed is KIT; the disease is neoplasm.